The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#SOHO2024: Mantle cell lymphoma
To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to mantle cell lymphoma below.
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 10, 2024
Reid Merryman, @DanaFarber, discusses evolving role of MRD in #lymphoma and the advancements in cfDNA assays for improving sensitivity of ctDNA detection, including ClonoSeq(R), CAPP-Seq, Avenio, PhaseED-Seq, and MAESTRO. Several clinical trials are adapting… pic.twitter.com/Tml1PRIGvE
CONGRESS | #SOHO2024@sairah__ahmed, @MDAndersonNews, discussed real world data on CAR T-cell therapy for MCL. Real-world effectiveness & safety of brexu-cel in patients with R/R MCL were similar to ZUMA-2 trial results:
— Lymphoma Hub (@lymphomahub) September 10, 2024
▪️ CIBMTR subgroup analysis by prior treatment: ORR was… pic.twitter.com/R0RWi4l1xy
CONGRESS | #SOHO2024 | POSTER@michaelwangmd @MDAndersonNews presents data from the phase III SYMPATICO trial, showing improved safety and efficacy of ibrutinib + venetoclax in patients with R/R MCL and TP53 mutations. N=74, mPFS=20.9, mOS=47.1 mo. #lymphoma #lymsm… pic.twitter.com/Q0kHIXayTJ
— Lymphoma Hub (@lymphomahub) September 9, 2024
CONGRESS | #SOHO2024@KrishPatelMD, @ProvSwedish, discusses novel investigational agents for the treatment of MCL, such as molecular glues/degraders, ADCs, novel CAR T cells, and BsAbs. Notable “off the shelf” therapies with meaningful activity include glofitimab monotherapy and… pic.twitter.com/vsVb5bgPuY
— Lymphoma Hub (@lymphomahub) September 9, 2024
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Craig Portell, @UVACancerCenter, discusses sequencing therapies in R/R MCL. He advises considering prior exposure to BTKi when managing relapse in MCL. If the patient hasn't been previously exposed, a BTKi should be started. If they’re actively on a BTKi at… pic.twitter.com/TccEL2LdWM
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Nina Wagner Johnston, @HopkinsMedicine, discusses the role of BTKi in frontline treatment of MCL. In older patients, addition of continuous ibrutinib to bendamustine and rituximab (BR) improved PFS however, worsened OS due to toxicity, while continuous… pic.twitter.com/KGvo5zQ1hB
CONGRESS | POSTER | #SOHO2024 | Tycel Phillips, MD @LymphClinician from @cityofhope introduced the phase III GLOBRYTE study which will compare fixed duration glofitamab monotherapy with rituximab+BR/Len for R/R #mantlecelllymphoma (N=182), with a primary endpoint of PFS.… pic.twitter.com/J4lBr0bk5Y
— Lymphoma Hub (@lymphomahub) September 4, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content